201 related articles for article (PubMed ID: 22818164)
1. Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease--what is the role of anti-TNF antibody?
Farkas K; Nagy F; Kovács L; Wittmann T; Molnár T
J Crohns Colitis; 2013 May; 7(4):e143-5. PubMed ID: 22818164
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab-induced lupus erythematosus with central nervous system involvement in a patient with Crohn's disease.
Vannucchi V; Grazzini M; Pieralli F; Giannotta M; Biagioni C; Nozzoli C
J Gastrointestin Liver Dis; 2011 Jun; 20(2):201-3. PubMed ID: 21725519
[TBL] [Abstract][Full Text] [Related]
3. Infliximab-induced psoriasis during therapy for Crohn's disease.
Steinwurz F; Denadai R; Saad-Hossne R; Queiroz ML; Teixeira FV; Romiti R
J Crohns Colitis; 2012 Jun; 6(5):610-6. PubMed ID: 22398095
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
[No Abstract] [Full Text] [Related]
5. Inflammatory bowel disease and lupus: a systematic review of the literature.
Katsanos KH; Voulgari PV; Tsianos EV
J Crohns Colitis; 2012 Aug; 6(7):735-42. PubMed ID: 22504032
[TBL] [Abstract][Full Text] [Related]
6. Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: the first case in the literature.
Sisman G; Erzin Y; Bal K
J Crohns Colitis; 2013 Oct; 7(9):e397-8. PubMed ID: 23583098
[No Abstract] [Full Text] [Related]
7. TNF-alpha antagonist induced lupus on three different agents.
Mudduluru BM; Shah S; Shamah S; Swaminath A
Postgrad Med; 2017 Mar; 129(2):304-306. PubMed ID: 27748629
[TBL] [Abstract][Full Text] [Related]
8. Infliximab-induced lupus in Crohn's disease: a case report.
Sarzi-Puttini P; Ardizzone S; Manzionna G; Atzeni F; Colombo E; Antivalle M; Carrabba M; Bianchi-Porro G
Dig Liver Dis; 2003 Nov; 35(11):814-7. PubMed ID: 14674674
[TBL] [Abstract][Full Text] [Related]
9. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
10. Systemic lupus erythematosus complicated by Crohn's disease: a case report and literature review.
Yamashita H; Ueda Y; Kawaguchi H; Suzuki A; Takahashi Y; Kaneko H; Kano T; Mimori A
BMC Gastroenterol; 2012 Dec; 12():174. PubMed ID: 23216789
[TBL] [Abstract][Full Text] [Related]
11. Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another?
Kocharla L; Mongey AB
Lupus; 2009 Feb; 18(2):169-71. PubMed ID: 19151120
[TBL] [Abstract][Full Text] [Related]
12. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
[TBL] [Abstract][Full Text] [Related]
13. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent.
Subramanian S; Yajnik V; Sands BE; Cullen G; Korzenik JR
Inflamm Bowel Dis; 2011 Jan; 17(1):99-104. PubMed ID: 20629183
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced lupus-like syndrome in ankylosing spondylitis treated with infliximab.
Mounach A; Ghazi M; Nouijai A; Ghozlani I; Achemlal L; Bezza A; El Maghraoui A
Clin Exp Rheumatol; 2008; 26(6):1116-8. PubMed ID: 19210883
[TBL] [Abstract][Full Text] [Related]
15. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
[TBL] [Abstract][Full Text] [Related]
16. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
Steenholdt C
Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
[TBL] [Abstract][Full Text] [Related]
17. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
Famenini S; Wu JJ
J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
[TBL] [Abstract][Full Text] [Related]
18. Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn's disease.
Hukkinen M; Pakarinen MP; Piekkala M; Koivusalo A; Rintala R; Kolho KL
J Crohns Colitis; 2014 Aug; 8(8):756-62. PubMed ID: 24447625
[TBL] [Abstract][Full Text] [Related]
19. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.
Han PD; Cohen RD
Drugs; 2004; 64(16):1767-77. PubMed ID: 15301561
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF Rechallenge After Infliximab Induced Lupus in Crohn's Disease.
Loebenstein M; Schulberg JD
Gastroenterology; 2020 Jun; 158(8):2069-2071. PubMed ID: 31945355
[No Abstract] [Full Text] [Related]
[Next] [New Search]
